- Home
- INCY vs RTO Comparison
INCY vs RTO Comparison
Compare INCY & RTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- RTO
- Stock Information
- Founded
- INCY 1991
- RTO 1925
- Country
- INCY United States
- RTO United Kingdom
- Employees
- INCY N/A
- RTO N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- RTO Business Services
- Sector
- INCY Health Care
- RTO Consumer Discretionary
- Exchange
- INCY Nasdaq
- RTO Nasdaq
- Market Cap
- INCY 14.2B
- RTO 13.1B
- IPO Year
- INCY 1993
- RTO N/A
- Fundamental
- Price
- INCY $75.23
- RTO $24.92
- Analyst Decision
- INCY Buy
- RTO Hold
- Analyst Count
- INCY 20
- RTO 1
- Target Price
- INCY $75.12
- RTO N/A
- AVG Volume (30 Days)
- INCY 1.3M
- RTO 627.9K
- Earning Date
- INCY 02-10-2025
- RTO 02-18-2025
- Dividend Yield
- INCY N/A
- RTO 2.36%
- EPS Growth
- INCY N/A
- RTO 24.34
- EPS
- INCY 0.15
- RTO 0.20
- Revenue
- INCY $4,075,860,000.00
- RTO $6,837,109,965.00
- Revenue This Year
- INCY $16.00
- RTO $4.09
- Revenue Next Year
- INCY $10.47
- RTO $3.00
- P/E Ratio
- INCY $499.49
- RTO $24.64
- Revenue Growth
- INCY 12.94
- RTO 12.40
- 52 Week Low
- INCY $50.35
- RTO $22.40
- 52 Week High
- INCY $83.95
- RTO $34.07
- Technical
- Relative Strength Index (RSI)
- INCY 59.31
- RTO 51.77
- Support Level
- INCY $72.60
- RTO $24.33
- Resistance Level
- INCY $75.18
- RTO $25.28
- Average True Range (ATR)
- INCY 1.72
- RTO 0.37
- MACD
- INCY 0.18
- RTO 0.13
- Stochastic Oscillator
- INCY 74.33
- RTO 70.72
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.